EcoR1 Capital — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
Anaginanagin.cominJun 2018
Anagin develops targeted therapies for neurological and psychiatric diseases caused by disrupted synaptic plasticity, including PTSD, traumatic brain injury, depression, neuropathic pain, Alzheimer's, and Parkinson's disease.
BiotechDigital HealthMedical DevicesIndianapolis, US
Jaswant Gidda(Executive Officer, Director)James Schulz(Executive Officer)Yvonne Lai(Executive Officer)
BoardNora Doherty(Director)Derek Small(Director)Anantha Shekhar(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.